Description: LDTI requires that reinsurance recoverables be recognized in a manner consistent with the liabilities of underlying direct contracts. Consider implications of multiple ceded reinsurance contracts (e.g., coinsurance and YRT on the same business) and how this impacts the calculation of the net premium ratio (NPR) and other related approximations. Explore different options when only some of the policies within a cohort are reinsured. Multiple interpretations of the components of the NPR formula exist. Two main approaches will be presented-standalone and integrated approach. Other considerations to be discussed include implications of closed-block reinsurance transactions at transition and subsequent to transition, contra-DAC, market risk benefits. Finally, explore the short-duration YRT approximation (1/2 Cx) compared to the long-duration calculation.

Description: Reinsurance transactions have become increasingly common in the annuity market as means to reduce risk, improve pricing, release capital, or exit a line of business. The market has become increasingly complex as it has grown. Insurance carriers and reinsurance providers now need to keep up with a growing range of reinsurance structures to manage their business efficiently. This session will detail the different types of annuity reinsurance transactions currently being executed in the market, the costs and benefits of different approaches, and recent trends in reinsurance structuring. At the conclusion of the session, you will understand the basics of how annuity reinsurance is being used in the market today as well as how to understand and evaluate potential reinsurance transactions.

Description: The U.S. life insurance industry has been increasing its exposure to complex assets, either directly as investors or via offshore reinsurance (e.g., Bermuda). In order to address regulatory concerns about such investments and reinsurance arrangements, the NAIC has begun multiple initiatives to improve disclosure and strengthen regulatory requirements, and the Bermuda Monetary Authority is also strengthening its requirements. Hear a summary of these initiatives, and get an update on the latest developments at the NAIC and at the Academy on these topics.

Description: IFRS 17 will be effective as of 1 Jan 2023 and provide opportunities as well as challenges to both Direct Writers and Reinsurers across the insurance industry. If the new framework is not fully understood, an implementation can elevate the risk of problems in financial reporting, product development, investment management and more. The transition to IFRS provides an opportunity for companies to optimize the financial position of the enterprise by implementing mitigating strategies to reduce the risks and challenges that IFRS brings to the table.

Description: Discuss a comparison of the U.S. general and insured population mortality experience and how COVID-19 and non-COVID-19 excess deaths impacted the populations differently. Discover the population mortality experience in the UK with a focus on the recent emergence of excess deaths for non-COVID causes. The long-term implications on the insured population will also be explored. Wrap up with a discussion of different conditions of long COVID, including organ impairments.

Description: Global life insurance companies started to utilize both external and internal reinsurance for a holistic group-wide capital and risk management. This is more evident in increasing use of reinsurance affiliates in Bermuda and/or reinsuring business to Bermuda-based external reinsurers.Come explore how varying and often competing objectives of capital and risk management is balanced or optimized through the use of internal and external reinsurance from a view of global direct life insurance and annuity writers who will present cases and share their objectives, concerns, and experience in a relatively comparable structure. Presenters will have a brief panel discussion on a couple of hot topics such as on-going enhancement of Bermuda's capital and reserve regulatory framework and use of internal reinsurance.Get ready to learn practical and emerging views of insurers on the effective use of internal and external reinsurance for risk and capital management.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: The Society of Actuaries is committed to fostering a more inclusive and diverse environment in the U.S. and elsewhere around the world for members, candidates and customers wherever they live. An important aspect of this commitment is dedicated research that the Society of Actuaries has sponsored to further advance this effort. Explore diversity, equity and inclusion issues from the aspect of retirement preparedness and other aging issues. Results from a recently released research report and author's views from an invitation to write essays on these issues will be presented with an opportunity for audience suggestions for future work.

Description: As the size of the life reinsurance market in Bermuda has grown to over half a trillion dollars at the end of 2021, more and more actuaries are getting involved with this 21 square mile North Atlantic island in one way or the other. Come explore a fundamental understanding of the Bermuda solvency framework and an overview of its upcoming changes.

Description: Gene therapy is a quickly evolving field and will continue to grow as a risk concern for many health plans, stop loss insurers and reinsurers. Currently, there are only two approved gene therapies in the U.S., but that number is expected to escalate starting in the fall of 2022. Revisit the experience plans have had with the first two gene therapies, discuss plan design and network considerations in light of gene therapy, and discuss the actual composition of the near-term pipeline along with a range of modeled financial impacts and considerations for payers.